First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427).
Adenoid cystic carcinoma
Cancer vaccine
Colorectal neoplasms
Glandular and epithelial neoplasms
Immune checkpoint therapy
Immunotherapy
Journal
Contemporary clinical trials communications
ISSN: 2451-8654
Titre abrégé: Contemp Clin Trials Commun
Pays: Netherlands
ID NLM: 101671157
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
07
01
2019
revised:
30
06
2019
accepted:
09
07
2019
entrez:
26
10
2019
pubmed:
28
10
2019
medline:
28
10
2019
Statut:
epublish
Résumé
MYB is a transcription factor that is overexpressed in colorectal cancer (CRC) and also a driver mutation in adenoid cystic carcinoma (AdCC). Therefore, the MYB protein is an ideal target to vaccinate against to aid recruitment of tumour infiltrating lymphocytes (TILs) against these tumours. The Peter MacCallum Cancer Centre (Melbourne, Australia) has engineered a DNA vaccine, TetMYB, based on the pVAX1 plasmid vector carrying a fusion construct consisting of the universal tetanus toxin T-cell epitopes flanking an inactivated This prospective first-in-human phase I single-arm multi-centre clinical trial involves patients with metastatic CRC or AdCC. Stage 1 will evaluate the safety profile of escalating doses of TetMYB vaccine, given sequentially and in combination with an anti-PD-1 inhibitory antibody, to determine the maximum tolerated dose (MTD). Stage 2 will assess the MTD in an expanded cohort. The calculated sample size is 32 patients: 12 in Stage 1 and 20 in Stage 2. The expected total duration of the trial is 3 years with 15 months of recruitment followed by a minimum of 18 months follow-up. MYB transcription factor is aberrantly overexpressed in a range of epithelial cancers, not limited to the above tumour types. Based on promising pre-clinical data of vaccine-induced tumour clearance and establishment of anti-tumour memory, we are embarking on this first-in-human trial. If successful, the results from this trial will allow progression to a Phase II trial and validation of this breakthrough immunotherapeutic approach, not only in CRC and AdCC, but other MYB over-expressing cancers. ClinicalTrials.gov ID: NCT03287427. Registered: September 19, 2017.
Sections du résumé
BACKGROUND
BACKGROUND
MYB is a transcription factor that is overexpressed in colorectal cancer (CRC) and also a driver mutation in adenoid cystic carcinoma (AdCC). Therefore, the MYB protein is an ideal target to vaccinate against to aid recruitment of tumour infiltrating lymphocytes (TILs) against these tumours. The Peter MacCallum Cancer Centre (Melbourne, Australia) has engineered a DNA vaccine, TetMYB, based on the pVAX1 plasmid vector carrying a fusion construct consisting of the universal tetanus toxin T-cell epitopes flanking an inactivated
METHODS
METHODS
This prospective first-in-human phase I single-arm multi-centre clinical trial involves patients with metastatic CRC or AdCC. Stage 1 will evaluate the safety profile of escalating doses of TetMYB vaccine, given sequentially and in combination with an anti-PD-1 inhibitory antibody, to determine the maximum tolerated dose (MTD). Stage 2 will assess the MTD in an expanded cohort. The calculated sample size is 32 patients: 12 in Stage 1 and 20 in Stage 2. The expected total duration of the trial is 3 years with 15 months of recruitment followed by a minimum of 18 months follow-up.
DISCUSSION
CONCLUSIONS
MYB transcription factor is aberrantly overexpressed in a range of epithelial cancers, not limited to the above tumour types. Based on promising pre-clinical data of vaccine-induced tumour clearance and establishment of anti-tumour memory, we are embarking on this first-in-human trial. If successful, the results from this trial will allow progression to a Phase II trial and validation of this breakthrough immunotherapeutic approach, not only in CRC and AdCC, but other MYB over-expressing cancers.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov ID: NCT03287427. Registered: September 19, 2017.
Identifiants
pubmed: 31650066
doi: 10.1016/j.conctc.2019.100409
pii: S2451-8654(19)30007-9
pii: 100409
pmc: PMC6804811
doi:
Banques de données
ClinicalTrials.gov
['NCT03287427']
Types de publication
Journal Article
Langues
eng
Pagination
100409Informations de copyright
© 2019 Published by Elsevier Inc.
Références
Sci Transl Med. 2016 Feb 24;8(327):327ra26
pubmed: 26912905
Nat Rev Cancer. 2008 Jul;8(7):523-34
pubmed: 18574464
Vaccine. 2010 Apr 1;28(16):2801-5
pubmed: 19941989
Am J Pathol. 2001 Apr;158(4):1289-99
pubmed: 11290547
Cancer Discov. 2016 Feb;6(2):125-7
pubmed: 26851182
Clin Cancer Res. 2016 Mar 15;22(6):1499-509
pubmed: 26515496
Genes Dev. 2011 Aug 1;25(15):1628-40
pubmed: 21828272
Int Immunol. 2016 Aug;28(8):373-82
pubmed: 27121213